Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Czock

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
Annals of Surgical Oncology|August 17, 2024
Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?Dirk Theile, David Czock
Therapeutische Umschau. Revue Therapeutique|December 25, 2010
[Drug-drug interactions and nephrotoxicity]David Czock, Frieder Keller
Clinical Nephrology|August 22, 2015
NephroPharmacology coming of ageFrieder Keller, David Czock
Clinical Pharmacokinetics|December 14, 2021
Clinical Pharmacokinetics and Pharmacodynamics of RoxadustatDavid Czock, Frieder Keller
Journal of Pharmacokinetics and Pharmacodynamics|October 2, 2007
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effectsDavid Czock, Frieder Keller
European Journal of Medical Research|June 11, 2005
Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?David Czock, F M Rasche
Kidney & Blood Pressure Research|July 17, 2004
New AUC-based method to estimate drug fraction removed by hemodialysisDavid Czock, Franz Maximilian Rasche
Deutsches Arzteblatt International|October 21, 2010
Drug therapy in patients with chronic renal failureBertram Hartmann, David Czock, Frieder Keller
European Journal of Drug Metabolism and Pharmacokinetics|December 20, 2013
Time of effect duration and administration interval for sitagliptin in patients with kidney failureFrieder Keller, Bertram Hartmann, David Czock
Deutsches Arzteblatt International|March 26, 2014
Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicalsNicolas Hohmann, Gerd Mikus, David Czock
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
Annals of Surgical Oncology|August 17, 2024
Perfusate Flow Rate: An Overlooked Factor in Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?Dirk Theile, David Czock
Therapeutische Umschau. Revue Therapeutique|December 25, 2010
[Drug-drug interactions and nephrotoxicity]David Czock, Frieder Keller
Clinical Nephrology|August 22, 2015
NephroPharmacology coming of ageFrieder Keller, David Czock
Clinical Pharmacokinetics|December 14, 2021
Clinical Pharmacokinetics and Pharmacodynamics of RoxadustatDavid Czock, Frieder Keller
Journal of Pharmacokinetics and Pharmacodynamics|October 2, 2007
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effectsDavid Czock, Frieder Keller
European Journal of Medical Research|June 11, 2005
Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?David Czock, F M Rasche
Kidney & Blood Pressure Research|July 17, 2004
New AUC-based method to estimate drug fraction removed by hemodialysisDavid Czock, Franz Maximilian Rasche
Deutsches Arzteblatt International|October 21, 2010
Drug therapy in patients with chronic renal failureBertram Hartmann, David Czock, Frieder Keller
European Journal of Drug Metabolism and Pharmacokinetics|December 20, 2013
Time of effect duration and administration interval for sitagliptin in patients with kidney failureFrieder Keller, Bertram Hartmann, David Czock
Deutsches Arzteblatt International|March 26, 2014
Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicalsNicolas Hohmann, Gerd Mikus, David Czock
Pageof 11